Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2018 | Asciminib plus traditonal TKIs for chronic phase CML

Giuseppe Saglio • 12 Sep 2018
SOHO 2018
Chronic Myeloid Leukemia Leukemia Asciminib Dasatinib Imatinib Nilotinib

Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting held in Houston, TX, Giuseppe Saglio, MD, of the University of Turin, Turin, Italy, gives us an update on the exciting trial of asciminib plus imatinib for chronic myeloid leukemia (CML) patients in the chronic phase (NCT03578367). Asciminib is a promising new TKI, which Dr Saglio refers to as a ‘fourth generation’ TKI, as he explains its mechanism of action.

More from Giuseppe Saglio

Prolonged follow-up of ASC4MORE: investigating the addition of asciminib to imatinib for CML
1:04
Prolonged follow-up of ASC4MORE: investigating the addition of asciminib to imatinib for CML
Giuseppe Saglio • 5 Mar 2025
Factors affecting adherence to TKI therapy in patients with CML
1:52
Factors affecting adherence to TKI therapy in patients with CML
Giuseppe Saglio • 5 Mar 2025
The use of asciminib in the frontline treatment of CML
4:12
The use of asciminib in the frontline treatment of CML
Giuseppe Saglio • 5 Mar 2025
Commonly observed side effects with asciminib and how to manage them
1:29
Commonly observed side effects with asciminib and how to manage them
Giuseppe Saglio • 5 Mar 2025

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals